chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient presented for vaccination at an on-site, employer sponsored wellness event around 1500 on September 30, 2021. After providing consent for vaccination and pharmacist evaluation of suitability as a candidate for vaccination, patient was administered a flu vaccine and COVID vaccine.  Approximately 10 minutes after vaccination (1510), patient returned to the vaccination area with complaints of an enlarging, reddened area on the right arm, but did not appear in any distress and denied difficulty breathing or symptoms or airway swelling.  Pharmacy personnel provided the patient with Benadryl 75mg (dose per patient request per her past routine with other allergic reactions) and Famotidine 20mg to be taken orally.  She then returned to her work area just down the hall from the vaccination clinic.  Approximately 8 minutes later (1518), one of the patient's co-workers presented to the vaccination clinic area with a request to assist the patient, as the patient was attempting to proceed back to the clinic area but was having difficulty (walking).  A pharmacist proceeded a short distance down the hallway and found the patient sitting upright on her own power in a chair in the hallway.  The patient had complaints of nausea and a "dry" pharangeal area which "didn't feel right" (she has since stated that it felt like she needed to clear her throat and couldn't).  Her right arm was erythematous but not swollen, and her feet bilaterally were appearing mildly erythematous.    Due to these symptoms, the pharmacist determined that dosing with an Epipen was warranted.  Per physician-signed pharmacy protocol and with the patient's knowledge and consent, the patient was administered epinephrine 0.3mg  via auto-injector into the lateral aspect of the left thigh at 1520, and emergency personnel were immediately summoned.  The patient's blood pressure  and pulse were checked with a  manual sphygmomanometer with the patient still in a seated position at 1523 and 1527, with readings of 145/90, pulse=110 and 135/85, pulse=108 respectively.  The patient was nauseated during this time period, had frequent belching, but no emesis noted.  While a third blood pressure and pulse were being attempted at 1532, emergency personnel arrived on the scene and took over care.  A report of all medications and care administered were given to ambulance personnel, as well as a copy of the immunization consent form (including vaccines administered).    Patient was transported to hospital for further evaluation and management.
Information received from a medical assistant who reported that a 20 years old pregnant female patient received her first dose of GARDASIL on 11-SEP-2012. Concomitant medications included prenatal vitamins. The patient's last menstrual period was 13-AUG-2012. No treatment was given. It was reported the patient sought unspecified medical attention. No further information was provided. This is a mended case: Information has been received from a medical assistant, for GARDASIL, a Pregnancy Registry product, concerning the 20 years old female patient with no drug reactions/allergies. The patient's history of previous pregnancies and live births were not known. The pregnant patient was vaccinated with her first dose of GARDASIL (lot # 1696AA, exp date: 12-SEP-2014, dose and route unspecified) on 11-SEP-2012. Patient had an LMP of 13-AUG-2012 and an EDD of 20-MAY-2013. Initial exposure to GARDASIL was at 4 weeks. The patient was exposed to GARDASIL during trimester 1. No treatment was given for  AE. The patient sought medical attention by an unknown method. Additional information has been requested.
Severe hives under right arm (armpit) extending down torso to near waist. Body aches and severe pain in left arm (shoulder area).
Has a rash across the chest.  I went to the doctor and was diagnosed with psoriasis. I also had a mammograms done.
Patient received the vaccine and then waited to pick up a prescription. As she was picking up her prescription (about 10 minutes after imz) she stated she felt dizzy, lightheaded, and warm.  Advised patient to immediately sit down. Provided a cold pack and applied to the back of her neck.  Sat with patient for approximately 15 minutes then she stated she felt better and wanted to leave. A technician walked the patient to her car and said she did not have any reaction.
This spontaneous report was received from a pharmacist and refers to a 63 year old female patient. The patient's concurrent conditions and medical history were not reported. On 09-NOV-2015, the patient was vaccinated with an expired dose of PNEUMOVAX23 (lot # K005402, expiration date: 07-NOV-2015), dose and route were not reported. No adverse effects were reported. Additional information has been requested.
This case was reported by a healthcare professional via a sales representative and described the occurrence of cellulitis in a subject of unspecified age and gender who was vaccinated with Infanrix, GlaxoSmithKline. On an unspecified date the subject received 5th dose of Infanrix (unknown). At an unspecified time after vaccination with Infanrix, on or before 30 August 2006, the subject experienced cellulitis from the shoulder to the elbow. The nurse was trying to determine "if there is an issue with the lot or if the injections were given subcutaneously rather than intramuscularly. This case was assessed as medically serious by GSK. The subject was treated with antibiotics (Antibiotic). At the time of reporting the events were resolved.
Information has been received from a lawyer regarding a case in litigation concerning a female patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. In 2011, the patient was vaccinated with ZOSTAVAX, (lot# and route unknown) for routine adult health maintenance for the prevention of shingles. The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster, also known as shingles and other complications. In 2015, the patient was treated at a medical facility for an infection caused by the blistering vesicular outbreak of herpes zoster or shingles, which was diagnosed as peripheral neuropathy. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX, for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering and other damages. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Upon internal review peripheral neuropathy was considered a medically significant event. Additional information has been requested.
Information has been received from a registered nurse referring to a 12 year old patient of unknown gender. On 07-AUG-2015 the patient was vaccinated with GARDASIL 9 (lot # L014415, intramuscular, expiration date and dose were unknown) which excursed the storage temperature (incorrect product storage). No reaction was reported. This is one of several reports received from the same reporter. Additional information has been requested.
extreme fatigue like when she had covid, hair shedding started a week later and has been ongoing
"Moderna COVID19 Vaccine EUA" I rcvd vaccine around 7pm n  about 12hrs after injection, 8/9 am, I started having terrible side effects. It reminded me of my symptoms when I had COVID back in February 2021. I was exhausted but couldnt sleep bc I had chills n a fever with the most awful body aches u can imagine. It really felt like days 4 n 5 of the actual virus! Totally dreading getting my 2nd dose now! Lol. But that only lasted until about 30 hrs after injection-around 12 am. The soreness in my arm started a few hours after injection but it was bearable and today its still sore but a lot better than yesterday. Just thought u should know in case it helps u understand this better!! Thanks for all u guys are doing!
No adverse effects reported; Multiple patients were vaccinated with improperly stored ROTATEQ on multiple dates; Information has been received from a medical assistant concerning a patient of unknown age, gender and race. The patient's medical history, drug allergies, previously drug reactions, concurrent conditions and concomitant medications were not reported.  On 29-MAY-2019, the patient was vaccinated with an improperly stored dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) orally for prophylaxis (lot number R029815 with expiration date in 18-JUN-2020) (strength and anatomical location were not provided).  The Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) was stored at an unknown temperature for an unknown time frame. There was a previous temperature excursion and the call was because of a data logger.  No adverse effects reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1907USA001848: US-009507513-1907USA001849: US-009507513-1906USA011434: US-009507513-1907USA001793: US-009507513-1907USA001794: US-009507513-1907USA001795: US-009507513-1907USA001796: US-009507513-1907USA001797: US-009507513-1907USA001798: US-009507513-1907USA001799: US-009507513-1907USA001800: US-009507513-1907USA001801: US-009507513-1907USA001802: US-009507513-1907USA001803: US-009507513-1907USA001804: US-009507513-1907USA001805: US-009507513-1907USA001806: US-009507513-1907USA001807: US-009507513-1907USA001808: US-009507513-1907USA001809: US-009507513-1907USA001810: US-009507513-1907USA001811: US-009507513-1907USA001812: US-009507513-1907USA001813: US-009507513-1907USA001814: US-009507513-1907USA001815: US-009507513-1907USA001816: US-009507513-1907USA001817: US-009507513-1907USA001818: US-009507513-1907USA001819: US-009507513-1907USA001820: US-009507513-1907USA001821: US-009507513-1907USA001822: US-009507513-1907USA001823: US-009507513-1907USA001824: US-009507513-1907USA001825: US-009507513-1907USA001826: US-009507513-1907USA001827: US-009507513-1907USA001828: US-009507513-1907USA001829: US-009507513-1907USA001830: US-009507513-1907USA001831: US-009507513-1907USA001832: US-009507513-1907USA001833: US-009507513-1907USA001834: US-009507513-1907USA001835: US-009507513-1907USA001836: US-009507513-1907USA001837: US-009507513-1907USA001838: US-009507513-1907USA001839: US-009507513-1907USA001840: US-009507513-1907USA001841: US-009507513-1907USA001842: US-009507513-1907USA001843: US-009507513-1907USA001844: US-009507513-1907USA001845: US-009507513-1907USA000965: US-009507513-1907USA001847: US-009507513-1907USA000952: US-009507513-1907USA000989: US-009507513-1907USA000962: US-009507513-1907USA000988: US-009507513-1907USA000963: US-009507513-1907USA000953: US-009507513-1907USA000959: US-009507513-1907USA000968: US-009507513-1907USA000967: US-009507513-1907USA000964: US-009507513-1907USA000966: US-009507513-1907USA000954: US-009507513-1907USA000969: US-009507513-1907USA000965:
She was administered Tdap vaccine when she had Tdap vaccine 11-11-05. No adverse effects reported by patient.
Itchy red rash on (L) chest and (L) forearm - not at site of vaccine. No breathing issues.
He reports getting the first Pfizer shot on 4/30/21. Starting on 5/1/21, he reports feeling fatigue, SOB and cough. These symptoms worsened over the subsequent two days until today when he felt that the cough was so frequent and severe that he couldn't breathe.  No fevers/chills/vomitting. He has felt nauseous and has dry heaved multiple times, mostly in the context of coughing fits. Pt was advised to go to ED for evaluation.
Information has been received from a physician concerning a 5 yr 3 month old male who on 22Mar05 was vaccinated with a dose of measles virus vaccine live  (Enders-Edmonston) (+) mumps virus vaccine live (Jeryl Lynn) (+) rubella virus vaccine live (Wistar RA 27/3) (lot 0771F). Subsequently the pt developed a rash with joint inflammation and fever. The pt was treated with diphenhydramine hydrochloride (Benadryl). The pt's status was reported as not recovered. No product quality complaint was involved. The reporter felt that the rash with joint inflammation and fever were other important medical events. Additional information has been requested.  This is in follow-up to report (s) previously submitted on 5/27/2005.  Initial and follow-up information has been received from a physician and a health care worker concerning a 5 year old male patient with asthma and a history of pneumonia who on 22-MAR-2005 was vaccinated in the right thigh with a second dose of MMR II (Lot # unknown).  The health care worker reported that the next day (also reported as 23-MAY-2005), the patient developed a swollen knee, 2 cm below the injection site.  The reporter indicated that an allergic reaction to the vaccine was questionable.  It was reported that the patient had an upper respiratory tract infection post-pneumonia at the time of vaccination.  The patient was given TYLENOL for pain and told to rest and elevate the leg.  Three days later (also reported as 27-MAY-2005), the office contacted the family and it was reported that the swelling had subsided.  The patient was reported to be recovered.  Additional information is not expected.
slight swelling; hypersensitivity reaction; intense pain sensation / of pain and agony; very sensitive to touch; pain is now radiating to the middle of her back; This case was reported by a consumer via call center representative and described the occurrence of local swelling in a 64-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 19th August 2020, the patient received the 1st dose of Shingrix. In September 2020, 3 weeks after receiving Shingrix, the patient experienced local swelling, hypersensitivity, pain, touch sensitivity increased and back pain. The patient was treated with ibuprofen (Advil) and lidocaine (Lidocaine Cream). On an unknown date, the outcome of the local swelling, hypersensitivity, pain and back pain were not recovered/not resolved and the outcome of the touch sensitivity increased was unknown.   It was unknown if the reporter considered the local swelling, hypersensitivity, pain, touch sensitivity increased and back pain to be related to Shingrix.  Additional details were provided as follows: The patient received the first dose of the Shingrix vaccine probably in her left arm (she was not sure).  About 3 weeks later the patient started to experience hypersensitivity reaction like the skin on the right shoulder blade was very sensitive to touch and she cannot wear any clothes as the cloth inflicted intense pain sensation. The patient stated there was slight swelling in the area and the hypersensitivity to pain radiated to the middle of her back and moved slightly to the left side. The stated this was slightly better than before. The patient's physician advised her to use lidocaine topical cream and Advil, but patient stated that it did not help. The patient was in a lot of pain and agony because of this. The reporter consented to follow up.
Pt. received wrong booster dose of vaccine.  Should have gotten 0.3ml, received 0.25ml instead.  Pt. was notified by me and will be offered a re-booster vaccine as soon as possible.
Started seeing floaters and flashes in my right (OD) eye approximately 3 hours after vaccine administration. These did not subside.  Scheduled an appointment with OD the following morning (10/4/22); eyes were dilated and the exam yielded a diagnosis of a vitreous detachment in said (OD) eye.
Pt recv vax on 9/14/98; on 9/16/98 pt exp rash on legs w/ itching, red, flat circular areas; tx=Benadryl.  On 9/19/98 rash spread to pt neck; pt to E.R.; tx=steroids injection.  On 9/23/98 pt exp vomiting;tx=steroid injection;dx=dermatitis
Tightness in chest; Trouble breathing, sometimes if patient inhale air, feel like need to cough; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 31Mar2021 at 09:30 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not receive any other medications within two weeks of vaccination. Patient did not report any known allergies to food, medications or other products. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 02Apr2021 at 19:00, the patient experienced tightness in the chest and trouble breathing. Sometimes if the patient inhaled air, the patient felt like need to cough. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the event tightness in chest and trouble breathing were not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
At the time of the 1st pfizer vaccine shot, I was 5 weeks 4 days pregnant.  I had no issues with the pregnancy.  I have been pregnant three times prior, naturally, with no issues carrying the pregnancy to term. My due date for the pregnancy was 12/4/21.  After receiving the vaccine on April 8, 2021, I felt cramping and a contraction type pain (one that would come and go) on April 12, 2021.  Four days after the pain, I experience spotting and increased bleeding until the confirmed miscarriage on April 22, 2021.
Area the day after vaccination was very red, swollen, itchy, painful and indurated.  Area was about 6cm in diameter.  Area remained swollen, red, itchy and painful for several days following vaccination.  Patient opted not to receive the second dose.
Pt received Moderna vaccines on 01/11/2021 and 02/08/2021. Pt presented to the ED on 10/29/21 with complaints of SOB, cough and nausea. Pt was found to be COVID positive with COVID pneumonia seen on CXR.
Had welt at injection site the size of golf ball with redness spreading from site out about the size of a baseball.  Site itched, redness with heat coming out of site for several days.  Arm soreness for 5-6 days afterwards.  Injection give on 12/22/2020 and today 1/6/2021 there still is soreness at injection site and slight redness of the area.
Pt states he started having terrible shivering starting 24 hours after administration of the vaccine and lasting for 24 hours. Pt did not seek medical attention.
Patient has a headache daily from the Pfizer COVID vaccine that she received on 5/11/2021.
This spontaneous report as received from a Registered Nurse refers to possibly 4 adult patients of unknown age. The reporter reported that another nurse gave possibly 4 adults LIQUID PEDVAXHIB (lot# was unknown) instead of hepatitis B virus vaccine(manufacturer was unknown). The patients were not experiencing any known symptoms. Additional information has been requested.
Pt became diaphoretic and nauseous once she was placed in waiting area.  Pt was placed on floor.  V/s obtained with HR 105 b/p 98/78 O2 100%.  Water was given with gaterade to drink.  Cold compress applied to neck.  A/ox3.  Pt vomit x1.  Denies any acute distress.
is fever a side effect of this vaccine?; This case was reported by a other health professional via interactive digital media and described the occurrence of fever in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced fever. On an unknown date, the outcome of the fever was unknown.   It was unknown if the reporter considered the fever to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but it was selected as adult as per the vaccine indication. The reporter asked if fever was a side effect of this vaccine.
Bell's Palsy  started 9/18/22 4:30PM noticed difficulty using a straw.  Mouth tongue felt like after a dental block. Hard to scrunch left eye. Droopy left side of mouth.  Blinking slower on Left eye. saw PCP 9/19/22 at 11;45AM  Confirmed Bell's Palsy.   TX: Prednisone 80 mg/day X 7 days          valacyclovir Hcl 1 gram tab  1 tab 3 x day for 7 days
After 2nd dose had a rash minor rash; This spontaneous case was reported by a consumer and describes the occurrence of RASH (After 2nd dose had a rash minor rash) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Chronic disease (Chronic illness).    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced RASH (After 2nd dose had a rash minor rash). At the time of the report, RASH (After 2nd dose had a rash minor rash) outcome was unknown.            No concomitant medications were mentioned. No treatment details were reported.   This case was linked to MOD-2021-413761 (Patient Link).
Pt vaccinated with DTP developed jerking of arms & legs for 15 seconds, eyes glassy appearance, probable seizure-occurred 1 hrs after vaccine given.
Increase vagal response after HPV shot, decrease BP, decrease HR, 98/60 ---> 88/56, 74---> 40
Became increasingly fussy, then had episode of eyes "rolling" back and mild jerking of limbs on 12/14/00 at about 23:00.
Suspicious of cellulitis; Skin reaction that included, swelling; Skin reaction that included, swelling, pain; Skin reaction that included, swelling, pain, redness; Injection site reactions presented with red streaks moving around the upper arm; This case was reported by a physician via sales rep and described the occurrence of injection site cellulitis in a 17-year-old female patient who received Men B NVS (Bexsero) for prophylaxis.   In July 2020, the patient received the 1st dose of Bexsero. In July 2020, 1 day after receiving Bexsero, the patient experienced injection site cellulitis, injection site swelling, injection site pain, injection site erythema and injection site abrasion. The patient was treated with sulfamethoxazole + trimethoprim (Bactrim). On an unknown date, the outcome of the injection site cellulitis, injection site swelling, injection site pain, injection site erythema and injection site abrasion were recovered/resolved.   It was unknown if the reporter considered the injection site cellulitis, injection site swelling, injection site pain, injection site erythema and injection site abrasion to be related to Bexsero.  Additional details were provided as follows: The age at vaccination was not reported. The patient received dose of Bexsero in July 2020 and experienced local skin reactions including swelling, pain, redness and red treaks moving around upper arm. The reporter stated that, the patient was seen in office and was suspicious of cellulitis. The patient treated with Bactrim for cellulitis. For the tolerance of 2nd dose refer case US2020AMR160427, reported for same patient.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020160534:FU1 deleted US-GLAXOSMITHKLINE-US2020AMR160427:same reporter